Jun 30, 2026 08:06AM
Jun 30, 2026 08:05AM
May 28, 2026 08:05AM
May 28, 2026 08:05AM
May 27, 2026 08:05AM
May 27, 2026 08:05AM
May 13, 2026 08:07AM Aptevo names Jeff Lamothe CEO, reports AML trial progress
May 13, 2026 08:05AM
May 6, 2026 08:10AM
May 6, 2026 08:05AM
Mar 26, 2026 08:05AM
Mar 19, 2026 08:05AM
Mar 10, 2026 08:21AM
Mar 10, 2026 08:05AM Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Feb 3, 2026 08:06AM
Feb 3, 2026 08:05AM
Jan 28, 2026 04:23PM
Jan 9, 2026 08:05AM
Jan 9, 2026 08:05AM
Dec 26, 2025 08:05AM
Dec 26, 2025 08:05AM Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Dec 9, 2025 08:07AM
Dec 9, 2025 08:05AM
Nov 10, 2025 08:05AM
Nov 10, 2025 08:05AM
Nov 6, 2025 08:05AM
Oct 8, 2025 08:20AM
Oct 1, 2025 04:34PM Aptevo Therapeutics (APVO) files for 6.9M share offering by selling stockholders
Sep 16, 2025 08:34AM
Sep 16, 2025 08:30AM
Sep 5, 2025 09:00AM
Sep 4, 2025 08:46AM
Sep 4, 2025 08:45AM
Aug 13, 2025 08:06AM
Aug 13, 2025 08:05AM Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Aug 11, 2025 10:53AM
Aug 11, 2025 08:05AM
Aug 8, 2025 09:00AM
Jul 25, 2025 04:18PM
Jun 20, 2025 11:30AM
Jun 20, 2025 11:30AM
Jun 20, 2025 08:55AM Aptevo Therapeutics (APVO) Expands Differentiated CD3 Portfolio with APVO455
Jun 20, 2025 08:55AM
Jun 18, 2025 10:53AM
Jun 18, 2025 10:52AM
Jun 18, 2025 10:52AM
Jun 18, 2025 08:07AM
Jun 18, 2025 08:01AM
Jun 13, 2025 08:05AM Aptevo Participating in the BIO International Convention
May 22, 2025 08:11AM

415,785 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All